JP7012089B2 - 皮膚炎および炎症性皮膚疾患の処置のためのカンナビノイドの製剤 - Google Patents

皮膚炎および炎症性皮膚疾患の処置のためのカンナビノイドの製剤 Download PDF

Info

Publication number
JP7012089B2
JP7012089B2 JP2019544865A JP2019544865A JP7012089B2 JP 7012089 B2 JP7012089 B2 JP 7012089B2 JP 2019544865 A JP2019544865 A JP 2019544865A JP 2019544865 A JP2019544865 A JP 2019544865A JP 7012089 B2 JP7012089 B2 JP 7012089B2
Authority
JP
Japan
Prior art keywords
skin
cbd
cannabinoids
hds
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019544865A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020508994A (ja
JP2020508994A5 (enExample
Inventor
ユージーン クーパー，
マシュー カラハン，
Original Assignee
ボタニクス ファーマシューティカルズ リミテッド
ボタニクス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900495A external-priority patent/AU2017900495A0/en
Application filed by ボタニクス ファーマシューティカルズ リミテッド, ボタニクス ファーマシューティカルズ， インコーポレイテッド filed Critical ボタニクス ファーマシューティカルズ リミテッド
Priority claimed from PCT/AU2018/050044 external-priority patent/WO2018148785A1/en
Publication of JP2020508994A publication Critical patent/JP2020508994A/ja
Publication of JP2020508994A5 publication Critical patent/JP2020508994A5/ja
Priority to JP2022005183A priority Critical patent/JP2022050641A/ja
Application granted granted Critical
Publication of JP7012089B2 publication Critical patent/JP7012089B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2019544865A 2017-02-15 2018-01-24 皮膚炎および炎症性皮膚疾患の処置のためのカンナビノイドの製剤 Expired - Fee Related JP7012089B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022005183A JP2022050641A (ja) 2017-02-15 2022-01-17 皮膚炎および炎症性皮膚疾患の処置のためのカンナビノイドの製剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762459363P 2017-02-15 2017-02-15
AU2017900495A AU2017900495A0 (en) 2017-02-15 Formulations of Cannabinoids for the Treatment of Dermatitis and Inflammatory Skin Diseases
AU2017900495 2017-02-15
US62/459,363 2017-02-15
PCT/AU2018/050044 WO2018148785A1 (en) 2017-02-15 2018-01-24 Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022005183A Division JP2022050641A (ja) 2017-02-15 2022-01-17 皮膚炎および炎症性皮膚疾患の処置のためのカンナビノイドの製剤

Publications (3)

Publication Number Publication Date
JP2020508994A JP2020508994A (ja) 2020-03-26
JP2020508994A5 JP2020508994A5 (enExample) 2020-12-17
JP7012089B2 true JP7012089B2 (ja) 2022-01-27

Family

ID=67766794

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019544865A Expired - Fee Related JP7012089B2 (ja) 2017-02-15 2018-01-24 皮膚炎および炎症性皮膚疾患の処置のためのカンナビノイドの製剤
JP2022005183A Withdrawn JP2022050641A (ja) 2017-02-15 2022-01-17 皮膚炎および炎症性皮膚疾患の処置のためのカンナビノイドの製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022005183A Withdrawn JP2022050641A (ja) 2017-02-15 2022-01-17 皮膚炎および炎症性皮膚疾患の処置のためのカンナビノイドの製剤

Country Status (8)

Country Link
US (1) US20210401768A1 (enExample)
EP (1) EP3582768A4 (enExample)
JP (2) JP7012089B2 (enExample)
CN (1) CN110545807B (enExample)
AU (1) AU2018221880B2 (enExample)
BR (1) BR112019017018A2 (enExample)
CA (1) CA3053500A1 (enExample)
IL (1) IL268720B2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020508992A (ja) * 2017-02-15 2020-03-26 ボタニクス ファーマシューティカルズ リミテッド ざ瘡の処置のためのカンナビノイドの製剤
BR112020014911A2 (pt) 2018-01-24 2020-12-08 Botanix Pharmaceuticals Ltd Regime de dosagem de canabinoide para dermatite e condições de pele inflamatórias
CN111000740A (zh) * 2020-01-07 2020-04-14 杭州百芮生物科技有限公司 一种添加大麻提取成分组合物、制备方法及其应用
CN111671885A (zh) * 2020-06-15 2020-09-18 中国人民解放军西部战区总医院 一种用于治疗放射性皮炎的药物
CN111514280A (zh) * 2020-06-15 2020-08-11 中国人民解放军西部战区总医院 一种预防放射性皮炎的药物
CN113479456A (zh) * 2021-04-06 2021-10-08 上海思乐得不锈钢制品有限公司 一种用于储运生物制品的真空容器
US20230039887A1 (en) * 2021-07-20 2023-02-09 Enveric Biosciences, Inc. Compositions for topical treatment of radiation dermatitis
US12059393B2 (en) 2022-02-11 2024-08-13 Akos Biosciences, Inc. Compositions for topical treatment of radiation dermatitis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130184354A1 (en) 2012-01-13 2013-07-18 Donna K. Jackson Silicone and Hylauronic Acid (HLA) Delivery Systems for Products by Sustainable Processes for Medical Uses Including Wound Management
JP2015516455A (ja) 2012-05-14 2015-06-11 アルミラル・ソシエダッド・アノニマＡｌｍｉｒａｌｌ， Ｓ．Ａ． 局所用医薬組成物
JP2015535281A (ja) 2012-11-06 2015-12-10 ロチャル インダストリーズ，エルエルシー 揮発性、疎水性溶媒を用いた生物学的に活性な薬剤の送達
US20160374958A1 (en) 2015-06-23 2016-12-29 Axim Biotechnologies, Inc. Anti-microbial composition comprising cannabinoids
JP2018507262A (ja) 2015-03-02 2018-03-15 アフギン ファーマ, エルエルシーAfgin Pharma, Llc カンナビノイドを用いた、局所局部的神経作用療法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0104268D0 (en) * 2001-02-21 2001-04-11 Unilever Plc Antiperspirant or deodorant compositions
ES2312643T5 (es) * 2001-07-18 2011-10-18 Unilever N.V. Composiciones para el tratamiento del cabello y/o del cuero cabelludo.
WO2008024408A2 (en) * 2006-08-22 2008-02-28 Theraquest Biosciences, Inc. Pharmaceutical formulations of cannabinoids for application to the skin and method of use
US20080292560A1 (en) * 2007-01-12 2008-11-27 Dov Tamarkin Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent
EP2444081B1 (en) * 2010-10-19 2015-04-08 Parenteral, A.S. A composition for the treatment of inflammatory diseases comprising boswellic acids and cannabidiol
GB201019240D0 (en) * 2010-11-15 2010-12-29 Vib Vzw Respiratory syncytical virus vaccine
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130184354A1 (en) 2012-01-13 2013-07-18 Donna K. Jackson Silicone and Hylauronic Acid (HLA) Delivery Systems for Products by Sustainable Processes for Medical Uses Including Wound Management
JP2015516455A (ja) 2012-05-14 2015-06-11 アルミラル・ソシエダッド・アノニマＡｌｍｉｒａｌｌ， Ｓ．Ａ． 局所用医薬組成物
JP2015535281A (ja) 2012-11-06 2015-12-10 ロチャル インダストリーズ，エルエルシー 揮発性、疎水性溶媒を用いた生物学的に活性な薬剤の送達
JP2018507262A (ja) 2015-03-02 2018-03-15 アフギン ファーマ, エルエルシーAfgin Pharma, Llc カンナビノイドを用いた、局所局部的神経作用療法
US20160374958A1 (en) 2015-06-23 2016-12-29 Axim Biotechnologies, Inc. Anti-microbial composition comprising cannabinoids

Also Published As

Publication number Publication date
AU2018221880B2 (en) 2023-08-17
JP2020508994A (ja) 2020-03-26
IL268720A (en) 2019-10-31
CN110545807B (zh) 2022-11-22
EP3582768A4 (en) 2020-11-18
AU2018221880A1 (en) 2019-09-05
BR112019017018A2 (pt) 2020-04-14
IL268720B2 (en) 2024-09-01
CN110545807A (zh) 2019-12-06
JP2022050641A (ja) 2022-03-30
US20210401768A1 (en) 2021-12-30
CA3053500A1 (en) 2018-08-23
IL268720B1 (en) 2024-05-01
EP3582768A1 (en) 2019-12-25

Similar Documents

Publication Publication Date Title
JP7012089B2 (ja) 皮膚炎および炎症性皮膚疾患の処置のためのカンナビノイドの製剤
JP7559173B2 (ja) 皮膚炎および炎症性皮膚状態のためのカンナビノイド投薬レジメン
WO2018148785A1 (en) Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases
JP2022185150A (ja) ざ瘡の処置のためのカンナビノイドの製剤
WO2018148787A1 (en) Formulations of cannabinoids for the treatment of psoriasis
WO2018148786A1 (en) Formulations of cannabinoids for the treatment of acne
JP2024012288A (ja) ざ瘡のためのカンナビノイド投薬レジメン
JP7515277B2 (ja) ロキソプロフェン配合皮膚外用剤
JP7592396B2 (ja) ロキソプロフェン及び可溶化剤を含有する皮膚外用剤
JP2020508991A (ja) 乾癬の処置のためのカンナビノイドの製剤
JP2020508993A (ja) ざ瘡を処置するための組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220117

R150 Certificate of patent or registration of utility model

Ref document number: 7012089

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees